Filtros de búsqueda

Lista de obras de Chiara Cremolini

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer

artículo científico publicado en 2015

A perspective on the current management of advanced colorectal cancer

artículo científico publicado en 2013

A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab

artículo científico publicado en 2017

A still missing piece of the FIRE-3 puzzle.

artículo científico publicado en 2016

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

artículo científico publicado en 2017

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3

artículo científico publicado en 2019

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

artículo científico publicado en 2018

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy

An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients

artículo científico publicado en 2012

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

artículo científico publicado en 2017

BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases

scientific article published on 01 December 2018

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

artículo científico publicado en 2015

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

artículo científico publicado en 2015

BRAF-mutated metastatic colorectal cancer between past and future.

artículo científico publicado en 2015

Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study

scientific article published on 08 March 2019

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial

artículo científico publicado en 2019

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

artículo científico publicado en 2010

Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

artículo científico publicado en 2009

Biomarkers and response to bevacizumab--letter

scientific article published on 01 February 2014

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

artículo científico publicado en 2017

Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis

artículo científico publicado en 2013

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

artículo científico publicado en 2010

Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics

artículo científico publicado en 2019

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab

artículo científico publicado en 2016

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.

artículo científico publicado en 2015

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy

scientific article published in Nature Communications

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

artículo científico publicado en 2017

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

scientific article published on 06 February 2019

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

artículo científico publicado en 2018

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

artículo científico publicado en 2013

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle

artículo científico publicado en 2012

Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib

scientific article published on 28 January 2019

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

artículo científico publicado en 2015

Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis

artículo científico

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

artículo científico publicado en 2016

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.

artículo científico publicado en 2016

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

artículo científico publicado en 2013

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

artículo científico publicado en 2015

FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis

artículo científico publicado en 2020

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

artículo científico publicado en 2015

First-line chemotherapy for mCRC—a review and evidence-based algorithm.

artículo científico

First-line therapy for mCRC - the influence of primary tumour location on the therapeutic algorithm.

artículo científico publicado en 2017

Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

artículo científico publicado en 2018

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.

artículo científico publicado en 2014

Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.

artículo científico publicado en 2016

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

artículo científico

Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.

artículo científico publicado en 2017

Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy.

artículo científico publicado en 2010

How the lab is changing our view of colorectal cancer

artículo científico publicado en 2016

Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3

artículo científico publicado en 2019

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

artículo científico publicado en 2014

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial

scientific article published on 29 September 2020

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

scientific article published on 04 February 2019

KRAS and BRAF genotyping of synchronous colorectal carcinomas

artículo científico publicado en 2014

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

artículo científico publicado en 2009

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

artículo científico publicado en 2019

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

artículo científico publicado en 2016

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

artículo científico publicado en 2010

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

artículo científico publicado en 2017

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

artículo científico publicado en 2009

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

artículo científico publicado en 2011

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.

artículo científico publicado en 2018

Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells

scientific article published on 01 June 2019

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial

artículo científico publicado en 2019

Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer.

artículo científico publicado en 2015

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer

artículo científico publicado en 2015

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer

scientific article published on 21 June 2018

Prevention and management of adverse events related to regorafenib

artículo científico publicado en 2014

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

artículo científico publicado en 2015

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy

scientific article published on 13 September 2018

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

artículo científico publicado en 2018

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.

artículo científico publicado en 2018

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.

artículo científico publicado en 2015

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.

artículo científico publicado en 2018

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

artículo científico publicado en 2016

Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.

artículo científico publicado en 2016

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

scientific article published on 01 March 2019

Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al.

artículo científico publicado en 2015

Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

artículo científico publicado en 2013

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

artículo científico publicado en 2011

Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience

scientific article published on 18 February 2019

Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.

artículo científico publicado en 2014

Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients

artículo científico publicado en 2016

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer

artículo científico publicado en 2017

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

artículo científico publicado en 2015

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis

artículo científico publicado en 2016

TAS-102 for the treatment of metastatic colorectal cancer.

artículo científico publicado en 2015

TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply

artículo científico publicado en 2015

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

artículo científico publicado en 2017

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer

artículo científico publicado en 2018

Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

artículo científico publicado en 2017

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

artículo científico publicado en 2018

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

artículo científico publicado en 2018

The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

scholarly article by Carlotta Antoniotti published in August 2018

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.

artículo científico

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial

scientific article published on 07 February 2019

Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO

artículo científico publicado en 2020

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

scientific article published on 08 May 2018

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

artículo científico publicado en 2016

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

artículo científico publicado en 2015

What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda